Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Mann, Jaclyn K ^a   Byakwaga, Helen ^b,c   Kuang, Xiaomei T ^d   Le, Anh Q ^d   Brumme, Chanson J ^e   Mwimanzi, Philip ^d   Omarjee, Saleha ^a   Martin, Eric ^d,e   Lee, Guinevere Q ^e   Baraki, Bemuluyigza ^d   Danroth, Ryan ^d   McCloskey, Rosemary ^d,e   Muzoora, Conrad ^b   Bangsberg, David R ^f   Hunt, Peter W ^c   Goulder, Philip J R ^g   Walker, Bruce D ^f,h,i   Harrigan, P R ^e   Martin, Jeff N ^c   Ndung'u, Thumbi ^a,h,j   Brockman, Mark A ^d,e   Brumme, Zabrina L ^d,e   more..

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SIMON FRASER UNIVERSITY   (Canada)

^e BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h HARVARD UNIVERSITY   (United States)

ⁱ Howard Hughes Institute   (United States)

^j MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

more..

Author keywords

CD4; HIV AIDS; HLA class I; Nef; Pathogenesis; Viral diversity

Indexed keywords

CD4 ANTIGEN; HLA ANTIGEN CLASS 1; NEF PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CLONE; CODON; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE D; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; STRAIN DIFFERENCE; UNINDEXED SEQUENCE; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AFRICA; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DOWN-REGULATION; FEMALE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; NORTH AMERICA;

EID: 84883810916     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-100     Document Type: Article

References (64)

1. Foster JL, Denial SJ, Temple BRS, Garcia JV. Mechanisms of HIV-1 Nef Function and Intracellular Signaling. J Neuroimmune Pharmacol 2011, 6:230-246. 10.1007/s11481-011-9262-y, 3777542, 21336563.
2. Geyer M, Fackler OT, Peterlin BM. Structure-function relationships in HIV-1 Nef. EMBO reports 2001, 21(7):580-585.
3. Mwimanzi P, Markle TJ, Ueno T, Brockman MA. Human leukocyte antigen (HLA) class I downregulation by human immunodeficiency virus type I negative factor (HIV-1 Nef): what might we learn from natural sequence variants?. Viruses 2012, 4:1711-1730. 10.3390/v4091711, 3499827, 23170180.
4. Foster JL, Garcia JV. HIV-1 Nef: at the crossroads. Retrovirology 2008, 5:84. doi: 10.1186/1742-4690-1185-1184, 10.1186/1742-4690-5-84, 2563024, 18808677.
5. Ross TM, Oran AE, Cullen BR. Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Curr Biol 1999, 9:613-621. 10.1016/S0960-9822(99)80283-8, 10375525.
6. Lundquist CA, Tobiume M, Zhou J, Unutmaz D, Aiken C. Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes. J Virol 2002, 76(9):4625-4633. 10.1128/JVI.76.9.4625-4633.2002, 155097, 11932428.
7. Argañaraz ER, Schindler M, Kirchhoff F, Cortes MJ, Lama J. Enhanced CD4 downmodulation by late stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication. J Biol Chem 2003, 278(36):33912-33919. 10.1074/jbc.M303679200, 12816953.
8. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10(6):661-671. 10.1016/S1074-7613(00)80065-5, 10403641.
9. Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65(4):651-662. 10.1016/0092-8674(91)90097-I, 2032289.
10. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270(5238):988-991. 10.1126/science.270.5238.988, 7481804.
11. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995, 332(4):228-232. 10.1056/NEJM199501263320405, 7808489.
12. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, Trocha A, Addo MM, Block BL, Rothchild AC, et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol 2008, 82(17):8422-8430. 10.1128/JVI.00535-08, 2519665, 18562530.
13. Corró G, Rocco CA, De Candia C, Catano G, Turk G, Mangano A, Aulicino PC, Bologna R, Sen L. Genetic and functional analysis of HIV type 1 nef gene derived from long-term nonprogressor children: association of attenuated variants with slow progression to pediatric AIDS. AIDS Res Hum Retroviruses 2012, 28(12):1617-1626. 10.1089/aid.2012.0020, 22583022.
14. Huang Y, Zhang L, Ho DD. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol 1995, 69:93-100. 188552, 7983771.
15. Mwimanzi P, Markle T, Otsuka H, Ogata Y, Tokunaga M, Miura T, Martin E, Pereyra F, Walker B, Brumme Z, et al. Impairment of viral replication capacity by nef alleles from HIV elite controllers. Retrovirology 2011, 8(Suppl2):53. 3136417, 21729311.
16. Mwimanzi P, Markle TJ, Martin E, Ogata Y, Kuang XT, Tokunaga M, Mahiti M, Pereyra F, Miura T, Walker BD, et al. Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology 2013, 10(1):1. 10.1186/1742-4690-10-1, 3564836, 23289738.
17. Jubier-Maurin V, Saragosti S, Perret JL, Mpoudi E, Esu-Williams E, Mulanga C, Liegeois F, Ekwalanga M, Delaporte E, Peeters M. Genetic characterization of the nef gene from human immunodeficiency virus type 1 group M strains representing genetic subtypes A, B, C, E, F, G, and H. AIDS Res Hum Retroviruses 1999, 15(1):23-32. 10.1089/088922299311673, 10024049.
18. Yoon K, Jeong JG, Yoon H, Lee JS, Kim S. Differential effects of primary human immunodeficiency virus type 1 nef sequences on downregulation of CD4 and MHC class I. Biochem Biophys Res Commun 2001, 284(3):638-642. 10.1006/bbrc.2001.5026, 11396948.
19. Turk G, Gundlach S, Carobene M, Schindler M, Salomon H, Benaroch P. Single Nef proteins from HIV type 1 subtypes C and F fail to upregulate invariant chain cell surface expression but are active for other functions. AIDS Res Hum Retroviruses 2009, 25(3):285-296. 10.1089/aid.2008.0132, 19327048.
20. Meuwissen PJ, Stolp B, Iannucci V, Vermeire J, Naessens E, Saksela K, Geyer M, Vanham G, Arien KK, Fackler OT, et al. Identification of a highly conserved valine-glycine-phenylalanine amino acid triplet required for HIV-1 Nef function. Retrovirology 2012, 9:34. 10.1186/1742-4690-9-34, 3476393, 22537596.
21. Abraha A, Nankya IL, Gibson R, Demers K, Tebit DM, Johnston E, Katzenstein D, Siddiqui A, Herrera C, Fischetti L, et al. CCR5- and CXCR4-tropic subtype C HIV-1 isolates have lower pathogenic fitness as compared to the other dominant group M subtypes: Implications for the epidemic. J Virol 2009, 83(11):5592-5605. 10.1128/JVI.02051-08, 2681953, 19297481.
22. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008, 358(15):1590-1602. 10.1056/NEJMra0706737, 2614444, 18403767.
23. Kanki PJ, Hamel DJ, Sankalé JL, Hsieh C, Thior I, Barin F, Woodcock SA, Guèye-Ndiaye A, Zhang E, Montano M, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999, 179(1):68-73. 10.1086/314557, 9841824.
24. Renjifo B, Gilbert P, Chaplin B, Msamanga G, Mwakagile D, Fawzi W, Essex M, . Tanzanian Vitamin and HIV Study Group Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS 2004, 18(12):1629-1636. 10.1097/01.aids.0000131392.68597.34, 15280773, Tanzanian Vitamin and HIV Study Group.
25. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quiñones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M, et al. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003, 77(2):1021-1038. 10.1128/JVI.77.2.1021-1038.2003, 140829, 12502818.
26. Velazquez-Campoy A, Todd MJ, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci USA 2001, 98(11):6062-6067. 10.1073/pnas.111152698, 33422, 11353856.
27. Iordanskiy S, Waltke M, Feng Y, Wood C. Subtype-associated differences in HIV-1 reverse transcription affect viral replication. Retrovirology 2010, 7:85. 10.1186/1742-4690-7-85, 2964588, 20939905.
28. Iwabu Y, Kinomoto M, Tatsumi M, Fujita H, Shimura M, Tanaka Y, Ishizaka Y, Nolan D, Mallal S, Sata T, et al. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J Biol Chem 2010, 285(46):35350-35358. 10.1074/jbc.M110.173286, 2975159, 20833716.
29. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, Berkhout B. Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J Virol 2000, 74(8):3740-3751. 10.1128/JVI.74.8.3740-3751.2000, 111883, 10729149.
30. Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard JM, Schwartz O. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998, 8(4):483-495. 10.1016/S1074-7613(00)80553-1, 9586638.
31. Rajapaksa US, Li D, Peng YC, McMichael AJ, Dong T, Xu XN. HLA-B may be more protective against HIV-1 than HLA-A because it resists negative regulatory factor (Nef) mediated downregulation. Proc Natl Acad Sci USA 2012, 109(33):13353-13358. 10.1073/pnas.1204199109, 3421200, 22826228.
32. Kirchhoff F, Easterbrook PJ, Douglas N, Troop M, Greenough TC, Weber J, Carl S, Sullivan JL, Daniels RS. Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol 1999, 73(7):5497-5508. 112607, 10364298.
33. Carl S, Greenough TC, Krumbiegel M, Greenberg M, Skowronski J, Sullivan JL, Kirchhoff F. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol 2001, 75(8):3657-3665. 10.1128/JVI.75.8.3657-3665.2001, 114857, 11264355.
34. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003, 51:229-240. 10.1093/jac/dkg079, 12562686.
35. Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog 2008, 4(8):e1000131. 10.1371/journal.ppat.1000131, 2515349, 18725938.
36. Mangasarian A, Piguet V, Wang JK, Chen YL, Trono D. Nef-induced CD4 and major histocompatibility complex class I (MHC-I) downregulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J Virol 1999, 73(3):1964-1973. 104438, 9971776.
37. Lewis MJ, Lee P, Ng HL, Yang OO. Immune selection in vitro reveals human immunodeficiency virus type 1 Nef sequence motifs important for its immune evasion function in vivo. J Virol 2012, 86(13):7126-7135. 10.1128/JVI.00878-12, 3416312, 22553319.
38. Yamada T, Kaji N, Odawara T, Chiba J, Iwamoto A, Kitamura Y. Proline 78 is crucial for human immunodeficiency virus type 1 Nef to downregulate class I human leukocyte antigen. J Virol 2003, 77(2):1589-1594. 10.1128/JVI.77.2.1589-1594.2003, 140770, 12502873.
39. Jia X, Singh R, Homann S, Yang H, Guatelli J, Xiong Y. Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef. Nat Struct Mol Biol 2012, 19(7):701-706. 10.1038/nsmb.2328, 3407041, 22705789.
40. Grzesiek S, Stahl SJ, Wingfield PT, Bax A. The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. Biochemistry 1996, 35:10256-10261.
41. Craig HM, Pandori MW, Guatelli JC. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 downregulation and optimal viral infectivity. Proc Natl Acad Sci USA 1998, 95(19):11229-11234. 10.1073/pnas.95.19.11229, 21624, 9736718.
42. Akari H, Arold S, Fukumori T, Okazaki T, Strebel K, Adachi A. Nef-induced major histocompatibility complex class I downregulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 downregulation. J Virol 2000, 74(6):2907-2912. 10.1128/JVI.74.6.2907-2912.2000, 111784, 10684310.
43. Kuo LS, Baugh LL, Denial SJ, Watkins RL, Liu M, Garcia JV, Foster JL. Overlapping effector interfaces define the multiple functions of the HIV-1 Nef polyproline helix. Retrovirology 2012, 9:47. 10.1186/1742-4690-9-47, 3464899, 22651890.
44. Poon AF, Swenson LC, Dong WW, Deng W, Kosakovsky Pond SL, Brumme ZL, Mullins JI, Richman DD, Harrigan PR, Frost SD. Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. Mol Biol Evol 2010, 27:819-832. 10.1093/molbev/msp289, 2877536, 19955476.
45. Preacher KJ. Calculation for the chi-square test: An interactive calculation tool for chi-square tests of goodness of fit and independence [Computer software]. 2001, Available from http://quantpsy.org.
46. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, Swenson LC, Tao I, Szeto S, Rosato P, et al. HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag. Pol and Nef Proteins. PLoS One 2009, 4(8):e6687. 10.1371/journal.pone.0006687, 2723923, 19690614.
47. Chopera DR, Mann JK, Mwimanzi P, Omarjee S, Kuang XT, Ndabambi N, Goodier S, Martin E, Naranbhai V, Abdool-Karim S, et al. No evidence for selection of HIV-1 with enhanced Gag-Protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. PLoS One 2013, 8(8):e71758. 10.1371/journal.pone.0071758, 3756015, 24015191.
48. Mwimanzi P, Markle T, Ogata Y, Martin E, Tokunaga M, Mahiti M, Kuang XT, Walker BD, Brockman MA, Brumme ZL, et al. Dynamic range of Nef functions in chronic HIV-1 infection. Virology 2013, 439(2):74-80. 10.1016/j.virol.2013.02.005, 23490051.
49. Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011, 11:45-56. 10.1016/S1473-3099(10)70186-9, 21126914.
50. Kiwanuka N, Robb M, Laeyendecker O, Kigozi G, Wabwire-Mangen F, Makumbi F, Nalugoda F, Kagaayi J, Eller M, Eller L, et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai District, Uganda. J Acquir Immune Defic Syndr 2010, 54(2):180-184. 2877752, 20010433.
51. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010, 13:4. 10.1186/1758-2652-13-4, 2827379, 20205896.
52. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, Mandaliya K, Jaoko W, Overbaugh J. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007, 195(8):1177-1180. 10.1086/512682, 17357054.
53. Alaeus A, Lidman K, Björkman A, Giesecke J, Albert J. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 1999, 13(8):901-907. 10.1097/00002030-199905280-00005, 10371170.
54. Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, Makhema J, Degruttola V, Walker BD, Essex M. Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS 2011, 25(12):1515-1522. 10.1097/QAD.0b013e3283471eb2, 3544358, 21505307.
55. Iafrate AJ, Carl S, Bronson S, Stahl-Hennig C, Swigut T, Skowronski J, Kirchhoff F. Disrupting surfaces of nef required for downregulation of CD4 and for enhancement of virion infectivity attenuates simian immunodeficiency virus replication in vivo. J Virol 2000, 74(21):9836-9844. 10.1128/JVI.74.21.9836-9844.2000, 102020, 11024110.
56. Swigut T, Alexander L, Morgan J, Lifson J, Mansfield KG, Lang S, Johnson RP, Skowronski J, Desrosiers R. Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus. J Virol 2004, 78(23):13335-13344. 10.1128/JVI.78.23.13335-13344.2004, 525019, 15542684.
57. Mwimanzi P, Hasan Z, Hassan R, Suzu S, Takiguchi M, Ueno T. Effects of naturally-arising HIV Nef mutations on cytotoxic T lymphocyte recognition and Nef's functionality in primary macrophages. Retrovirology 2011, 8:50. 10.1186/1742-4690-8-50, 3131245, 21696586.
58. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugyenyi P, Bangsberg DR. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004, 36(5):1100-1102. 10.1097/00126334-200408150-00014, 15247564.
59. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, Kembabazi A, Neilands TB, Bangsberg DR, Deeks SG, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011, 25(17):2123-2131. 10.1097/QAD.0b013e32834c4ac1, 3480326, 21881481.
60. Brumme ZL, Brumme CJ, Heckerman D, Korber BT, Daniels M, Carlson J, Kadie C, Bhattacharya T, Chui C, Szinger J, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007, 3(7):0913-0927.
61. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, Wang B, Losina E, Miura T, Chonco F, et al. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol 2010, 84(20):10820-10831. 10.1128/JVI.01084-10, 2950592, 20702636.
62. Kosakovsky Pond SL, Frost SD, Muse SV. HyPhy: hypothesis testing using phylogenies. Bioinformatics 2005, 21(5):676-679. 10.1093/bioinformatics/bti079, 15509596.
63. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 2003, 52(5):696-704. 10.1080/10635150390235520, 14530136.
64. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003, 100:9440-9445. 10.1073/pnas.1530509100, 170937, 12883005.